Get ahead of the patient storm with TASCENSO ODT® (fingolimod)

At the end 2023, Gilenya® (fingolimod) capsules product support will come to an end.¹ This could result in a storm of patients calling you at the same time when they can no longer access their co-pay support, causing a significant burden to you and your clinic.To avoid this headache you could get ahead by proactively switching your patients to TASCENSO ODT, which is not a generic but is the same proven fingolimod you are familiar with.² It also comes with a Co-Pay Assistance Program where commercially insured eligible* patients may pay as little as $0. 

TASCENSO ODT is a treatment for patients with MS who want to remain on fingolimod treatment while benefitting from Cycle Vita™, which provides individualized product support* as unique as your patients.

Product

Find out more about the orally disintegrating tablet, including how it can be taken.

Support

Read more about our dedicated hub support program, Cycle Vita.

Graph Icon

Efficacy and Safety

See the efficacy and safety data, and learn more about its bioequivalence.

Enroll Icon

Enroll

Download the enrollment form to enroll your patients on TASCENSO ODT.

Tascenso Dissolve Icon

Product

TASCENSO ODT is the same proven fingolimod you are familiar with, but it comes in a unique orally disintegrating tablet formulation.3

  • Unique orally disintegrating tablet for MS treatment
  • Same proven fingolimod
  • Same efficacy & safety as Gilenya®**
  • A similar lowering of lymphocyte counts and effect on heart rate as Gilenya®4
  • Not a generic2
  • Not substitutable at the pharmacy level2
  • Each and every batch tested
  • Dissolves on the tongue in seconds
  • Taken once daily, with or without food and with or without water
  • Available as 0.25 mg and 0.5 mg orally disintegrating tablets
Find out more
Tascenso Care Icon

Support

We know that life-changing treatments need a support system which is tailored to the unique challenges your patients face. That’s why we created Cycle Vita, our dedicated hub support program, which delivers individualized product support* at every step. Including:

  • TASCENSO Time Program: Access to in-home first dose observation and baseline assessments as necessary
  • $0 Co-pay Assistance Program: Commercially insured eligible patients may pay as little as $0
  • Bridge Program: For patients taking another fingolimod treatment, a free supply of TASCENSO ODT is available to ensure the continuation of therapy while Cycle Vita secures appropriate benefit verification and prior authorization, if necessary
  • Hub Support: Including financial, logistics and medication adherence support
Find out more

“There could be a whole number of patients calling you with the same issue of being on a generic, not having co-pay support, not being able to afford their medication. This is a huge concern for fingolimod”

Dr Scagnelli, MD, Raleigh Neurology

John Scagnelli

Why not start by identifying which patients you could transition over now and get ahead of the storm? Cycle Vita will help make the transition as seamless as possible for you.

Download an enrollment form to enroll a patient in TASCENSO ODT. Complete all the required fields either digitally or by printing it. You can then either fax the form to Cycle Vita at + 1 (888) 385-8482 or email it to hello@cyclevita.life.

As soon as a completed enrollment form is sent to Cycle Vita, we can provide individualized support to eligible* patients.

Download Form

References

1. Gilenya, 2022. Frequently Asked Questions About Gilenya. Accessed August 22nd, 2023. Available: https://www.gilenya.com/multiple-sclerosis/faqs

2. FDA., 2023. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. Accessed April 25th 2023. Available: https://www.accessdata.fda.gov/scripts/cder/ob/index.cfm

3. TASCENSO ODT (fingolimod). Prescribing Information. Cycle Pharmaceuticals Ltd.

4. Data on File: REF-00075

* Some areas of support may not be accessible to all patients. Eligibility criteria may apply to ensure compliance with all applicable federal and state requirements, and benefits may be limited to commercially insured patients only. For more detailed information about eligibility, terms and conditions, please contact the Cycle Vita team at +1 (888) 360-8482.

** Gilenya® is a registered trademark of Novartis AG.